Cytokine gene polymorphism and progression of renal and cardiovascular diseases

Kidney International

Volumn 72, Issue 5, 2007, Pages 549-556

  Rao, M ^a   Wong, C ^b   Kanetsky, P ^c   Girndt, M ^d   Stenvinkel, P ^e   Reilly, M ^c   Raj, D S C ^b  

^a TUFTS MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEW MEXICO HEALTH SCIENCES CENTER   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d SAARLAND UNIVERSITY   (Germany)

^e KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

End stage renal disease; Epigenetics; Haplotype; Hemodialysis; Inflammation

Indexed keywords

CYTOKINE; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 6; MARKER; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

CACHEXIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CYTOKINE RELEASE; DISEASE COURSE; DISEASE PREDISPOSITION; DNA POLYMORPHISM; EARLY INTERVENTION; EPIGENETICS; GENE ACTIVATION; GENE REPRESSION; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC TRANSCRIPTION; HAPLOTYPE; HIGH RISK PATIENT; HUMAN; INCIDENCE; INFLAMMATION; KIDNEY DISEASE; KIDNEY FAILURE; MORBIDITY; MORTALITY; PHENOTYPE; PREVALENCE; PRIORITY JOURNAL; SHORT SURVEY; SINGLE NUCLEOTIDE POLYMORPHISM;

CARDIOVASCULAR DISEASES; CYTOKINES; DISEASE PROGRESSION; HUMANS; INFLAMMATION; KIDNEY DISEASES; POLYMORPHISM, GENETIC;

EID: 34548145570     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/sj.ki.5002391     Document Type: Short Survey

References (64)

1. Coresh J, Wei GL, McQuillan G et al. Prevalence of high blood pressure and elevated serum creatinine level in the United States: findings from the third National Health and Nutrition Examination Survey (1988-1994). Arch Intern Med 2001; 161: 1207-1216.
2. Amento EP, Ehsani N, Palmer H, Libby P. Cytokines and growth factors positively and negatively regulate interstitial collagen gene expression in human vascular smooth muscle cells. Arterioscler Thromb 1991; 11: 1223-1230.
3. Ross R. Atherosclerosis -an inflammatory disease. N Engl J Med 1999; 340: 115-126.
4. Takeda K, Akira S. TLR signaling pathways. Semin Immunol 2004; 16: 3-9.
5. Libby P, Friedman GB, Salomon RN. Cytokines as modulators of cell proliferation in fibrotic diseases. Am Rev Respir Dis 1989; 140: 1114-1117.
6. Campbell GR, Chamley-Campbell JH. Invited review: the cellular pathobiology of atherosclerosis. Pathology 1981; 13: 423-440.
7. Boswell JM, Yui MA, Burt DW, Kelley VE. Increased tumor necrosis factor and IL-1 beta gene expression in the kidneys of mice with lupus nephritis. J Immunol 1988; 141: 3050-3054.
8. el Nahas AM. Growth factors and glomerular sclerosis. Kidney Int 1992; (Suppl 36): S15-S20.
9. Ketteler M, Noble NA, Border WA. Transforming growth factor-beta and angiotensin II: the missing link from glomerular hyperfiltration to glomerulosclerosis? Annu Rev Physiol 1995; 57: 279-295.
10. Montinaro V, Hevey K, Aventaggiato L et al. Extrarenal cytokines modulate the glomerular response to IgA immune complexes. Kidney Int 1992; 42: 341-353.
11. Nakamura T, Miller D, Ruoslahti E, Border WA. Production of extracellular matrix by glomerular epithelial cells is regulated by transforming growth factor-beta 1. Kidney Int 1992; 41: 1213-1221.
12. Coleman DL, Ruef C. Interleukin-6: an autocrine regulator of mesangial cell growth. Kidney Int 1992; 41: 604-606.
13. Horii Y, Muraguchi A, Iwano M et al. Involvement of IL-6 in mesangial proliferative glomerulonephritis. J Immunol 1989; 143: 3949-3955.
14. Bevilacqua MP, Pober JS, Majeau GR et al. Recombinant tumor necrosis factor induces procoagulant activity in cultured human vascular endothelium: characterization and comparison with the actions of interleukin 1. Proc Natl Acad Sci USA 1986; 83: 4533-4537.
15. Sharma K, Cook A, Smith M et al. TGF-beta impairs renal autoregulation via generation of ROS. Am J Physiol Renal Physiol 2005; 288: F1069-F1077.
16. Park S, Chang YH, Cho YJ et al. Cytokine-regulated expression of vascular cell adhesion molecule-1 in human glomerular endothelial cells. Transplant Proc 1998; 30: 2395-2397.
17. Zager RA, Johnson A. Renal cortical cholesterol accumulation is an integral component of the systemic stress response. Kidney Int 2001; 60: 2299-2310.
18. Atkins RC. Interleukin-1 in crescentic glomerulonephritis. Kidney Int 1995; 48: 576-586.
19. Border WA, Noble NA. Interactions of transforming growth factor-beta and angiotensin II in renal fibrosis. Hypertension 1998; 31: 181-188.
20. Benigni A, Remuzzi G. How renal cytokines and growth factors contribute to renal disease progression. Am J Kidney Dis 2001; 37: S21-S24.
21. Dzau VJ. The role of mechanical and humoral factors in growth regulation of vascular smooth muscle and cardiac myocytes. Curr Opin Nephrol Hypertens 1993; 2: 27-32.
22. Klahr S, Morrissey JJ. The role of vasoactive compounds, growth factors and cytokines in the progression of renal disease. Kidney Int 2000; 57(Suppl 75): S7-S14.
23. Locatelli F, Del Vecchio L, Andrulli S et al. The role of underlying nephropathy in the progression of renal disease. Kidney Int 2000; 57(Suppl 75): S49-S55.
24. Satko SG, Freedman BI, Moossavi S. Genetic factors in end-stage renal disease. Kidney Int 2005; 67(Suppl 94): S46-S49.
25. Yoshino M, Kuhlmann MK, Kotanko P et al. International differences in dialysis mortality reflect background general population atherosclerotic cardiovascular mortality. J Am Soc Nephrol 2006; 17: 3510-3519.
26. Lazarus R, Vercelli D, Palmer LJ et al. Single nucleotide polymorphisms in innate immunity genes: abundant variation and potential role in complex human disease. Immunol Rev 2002; 190: 9-25.
27. Pociot F, Molvig J, Wogensen L et al. A TaqI polymorphism in the human interleukin-1 beta (IL-1 beta) gene correlates with IL-1 beta secretion in vitro. Eur J Clin Invest 1992; 22: 396-402.
28. Amoli MM, Calvino MC, Garcia-Porrua C et al. Interleukin 1beta gene polymorphism association with severe renal manifestations and renal sequelae in Henoch-Schonlein purpura. J Rheumatol 2004; 31: 295-298.
29. Blakemore AI, Cox A, Gonzalez AM et al. Interleukin-1 receptor antagonist allele (IL1RN*2) associated with nephropathy in diabetes mellitus. Hum Genet 1996; 97: 369-374.
30. Tarlow JK, Blakemore AI, Lennard A et al. Polymorphism in human IL-1 receptor antagonist gene intron 2 is caused by variable numbers of an 86-bp tandem repeat. Hum Genet 1993; 91: 403-404.
31. Brull DJ, Montgomery HE, Sanders J et al. Interleukin-6 gene -174g>c and -572g>c promoter polymorphisms are strong predictors of plasma interleukin-6 levels after coronary artery bypass surgery. Arterioscler Thromb Vasc Biol 2001; 21: 1458-1463.
32. Losito A, Kalidas K, Santoni S, Jeffery S. Association of interleukin-6 -174G/C promoter polymorphism with hypertension and left ventricular hypertrophy in dialysis patients. Kidney Int 2003; 64: 616-622.
33. Girndt M, Kaul H, Sester U et al. Anti-inflammatory interleukin-10 genotype protects dialysis patients from cardiovascular events. Kidney Int 2002; 62: 949-955.
34. Eskdale J, Gallagher G, Verweij CL et al. Interleukin 10 secretion in relation to human IL-10 locus haplotypes. Proc Natl Acad Sci USA 1998; 95: 9465-9470.
35. Balakrishnan VS, Guo D, Rao M et al. Cytokine gene polymorphisms in hemodialysis patients: association with comorbidity, functionality, and serum albumin. Kidney Int 2004; 65: 1449-1460.
36. Udalova IA, Nedospasov SA, Webb GC et al. Highly informative typing of the human TNF locus using six adjacent polymorphic markers. Genomics 1993; 16: 180-186.
37. Aziz TM, Burgess M, Hasleton PS et al. Transforming growth factor-beta: association with arteriosclerosis and left ventricular dysfunction after heart transplantation. Transplant Proc 2001; 33: 2334-2336.
38. de Craen AJ, Posthuma D, Remarque EJ et al. Heritability estimates of innate immunity: an extended twin study. Genes Immun 2005; 6: 167-170.
39. Retterstol L, Eikvar L, Berg K. A twin study of C-reactive protein compared to other risk factors for coronary heart disease. Atherosclerosis 2003; 169: 279-282.
40. Feldman HI, Appel LJ, Chertow GM et al. The Chronic Renal Insufficiency Cohort (CRIC) Study: design and methods. J Am Soc Nephrol 2003; 14: S148-S153.
41. Carlson CS, Eberle MA, Rieder MJ et al. Selecting a maximally informative set of single-nucleotide polymorphisms for association analyses using linkage disequilibrium. Am J Hum Genet 2004; 74: 106-120.
42. Shu KH, Lee SH, Cheng CH et al. Impact of interleukin-1 receptor antagonist and tumor necrosis factor-alpha gene polymorphism on IgA nephropathy. Kidney Int 2000; 58: 783-789.
43. Shu KH, Cheng CH, Wu MJ et al. Interleukin 1 receptor antagonist and tumor necrosis factor-alpha gene polymorphism in patients with end-stage renal failure. Ren Fail 2005; 27: 53-57.
44. Kitamura A, Hasegawa G, Obayashi H et al. Interleukin-6 polymorphism (-634C/G) in the promotor region and the progression of diabetic nephropathy in type 2 diabetes. Diabet Med 2002; 19: 1000-1005.
45. Liu Y, Berthier-Schaad Y, Fallin MD et al. IL-6 haplotypes, inflammation, and risk for cardiovascular disease in a multiethnic dialysis cohort. J Am Soc Nephrol 2006; 17: 863-870.
46. Khalil MS, el Nahas AM, Blakemore AI. Transforming growth factor-beta1 SNPs: genetic and phenotypic correlations in progressive kidney insufficiency. Nephron Exp Nephrol 2005; 101: e31-e41.
47. Sato F, Narita I, Goto S et al. Transforming growth factor-beta1 gene polymorphism modifies the histological and clinical manifestations in Japanese patients with IgA nephropathy. Tissue Antigens 2004; 64: 35-42.
48. Rao M, Guo D, Jaber BL et al. Transforming growth factor-beta 1 gene polymorphisms and cardiovascular disease in hemodialysis patients. Kidney Int 2004; 66: 419-427.
49. Thibaudin D, Thibaudin L, Berthoux P et al. TNFA2 and d2 alleles of the tumor necrosis factor alpha gene polymorphism are associated with onset/occurrence of idiopathic membranous nephropathy. Kidney Int 2007; 71: 431-437.
50. Maury CP, Liljestrom M, Laiho K et al. Anaemia of chronic disease in AA amyloidosis is associated with allele 2 of the interleukin-1beta-511 promoter gene and raised levels of interleukin-1beta and interleukin-18. J Intern Med 2004; 256: 145-152.
51. Rao M, Guo D, Perianayagam MC et al. Plasma interleukin-6 predicts cardiovascular mortality in hemodialysis patients. Am J Kidney Dis 2005; 45: 324-333.
52. Fishman D, Faulds G, Jeffery R et al. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest 1998; 102: 1369-1376.
53. Turner DM, Williams DM, Sankaran D et al. An investigation of polymorphism in the interleukin-10 gene promoter. Eur J Immunogenet 1997; 24: 1-8.
54. Ortiz A, Bustos C, Alonso J et al. Involvement of tumor necrosis factor-alpha in the pathogenesis of experimental and human glomerulonephritis. Adv Nephrol Necker Hosp 1995; 24: 53-77.
55. Hajeer AH, Hutchinson IV. TNF-alpha gene polymorphism: clinical and biological implications. Microsc Res Tech 2000; 50: 216-228.
56. Udalova IA, Nedospasov SA, Webb GC et al. Highly informative typing of the human TNF locus using six adjacent polymorphic markers. Genomics 1993; 16: 180-186.
57. Herrmann SM, Ricard S, Nicaud V et al. Polymorphisms of the tumour necrosis factor-alpha gene, coronary heart disease and obesity. Eur J Clin Invest 1998; 28: 59-66.
58. Thibaudin D, Thibaudin L, Berthoux P et al. TNFA2 and d2 alleles of the tumor necrosis factor alpha gene polymorphism are associated with onset/occurrence of idiopathic membranous nephropathy. Kidney Int 2007; 71: 431-437.
59. Cambien F, Ricard S, Troesch A et al. Polymorphisms of the transforming growth factor-beta 1 gene in relation to myocardial infarction and blood pressure. The Etude Cas-Temoin de l'Infarctus du Myocarde (ECTIM) study. Hypertension 1996; 28: 881-887.
60. Stenvinkel P, Heimburger O, Paultre F et al. Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int 1999; 55: 1899-1911.
61. Pecoits-Filho R, Nordfors L, Lindholm B et al. Genetic approaches in the clinical investigation of complex disorders: malnutrition, inflammation, and atherosclerosis (MIA) as a prototype. Kidney Int 2003; (Suppl): S162-S167.
62. Reiner SL. Epigenetic control in the immune response. Hum Mol Genet 2005; 14(Spec. no. 1): R41-R46.
63. Mackay CR. CCL3L1 dose and HIV-1 susceptibility. Trends Mol Med 2005; 11: 203-206.
64. Basso F, Lowe GD, Rumley A et al. Interleukin-6 -174G>C polymorphism and risk of coronary heart disease in West of Scotland Coronary Prevention Study (WOSCOPS). Arterioscler Thromb Vasc Biol 2002; 22: 599-604.